Upfront Briefing
Gilead is set to acquire Arcellx for $7.8B, making a clear statement in multiple myeloma cell therapy (big number, bigger intent).
Regulators also stayed busy: FDA issued draft guidance for individualized rare disease therapies, while Novo Nordisk’s CagriSema didn’t match Lilly’s Zepbound in a head-to-head — not the kind of differentiation slide you want in obesity.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,837.8 |
(1.0%) |
(0.1%) |
| Nasdaq 100 |
24,708.9 |
(1.2%) |
(2.1%) |
| Russell 2000 |
2,621.0 |
(1.6%) |
+5.6% |
| Healthcare (XLV) |
158.5 |
+1.1% |
+2.4% |
| Biotech (XBI) |
127.0 |
+1.8% |
+4.1% |
| Nasdaq Biotech (NBI) |
6,014.1 |
+0.6% |
+5.4% |
| Clinical Trials (BBC) |
41.4 |
+1.4% |
+7.3% |
|
-
Risk-off tape: U.S. equities sold off on renewed tariff uncertainty and continued pressure on software/cyber names viewed as vulnerable to AI-driven disruption.
-
Rotation mattered: Healthcare finished green while the S&P/Nasdaq sank — classic “hide in defensives” positioning on macro noise.
-
Biotech outperformed on deal tape + idiosyncratic support (Arcellx takeout reset comps in late-stage oncology/cell therapy), even as broader growth derated.
-
Market data: U.S. close Mon 23-Feb-2026.
The Big 3
|
1
|
Gilead to acquire Arcellx for $7.8B in myeloma cell therapy deal
|
-
Gilead will pay $115/share cash + a $5 CVR (sales-based) to collapse its Arcellx partnership and take full control of anito-cel as it approaches a potential commercial window.
-
Why it matters:
This is “buy the partner, own the economics” at the point of maximum de-risk: anito-cel is already on FDA review, so Gilead is paying for control of manufacturing + commercialization ahead of launch.
The $5 CVR (sales-hurdle) keeps the headline big while forcing real commercial execution — and it resets comps for late-stage myeloma/cell-therapy assets where the registrational path is visible.
-
Source:
BioCentury
|
|
2
|
FDA issues draft guidance for individualized rare disease therapies
|
-
The FDA has released draft guidance for bespoke and individualized therapies, particularly for extremely rare diseases, potentially streamlining approval processes.
-
Why it matters:
FDA is putting real scaffolding around approvals where conventional trials are impossible.
If adopted, this can lower time/cost-to-proof for ultra-rare programs and advantage platforms that can repeatedly manufacture, characterize, and justify “individualized” products — i.e., a potential capital re-rate for teams with scalable CMC + regulatory muscle rather than one-off anecdotes.
-
Source:
STAT
-
More:
Endpoints; BioSpace; BioPharma Dive
|
|
3
|
Novo Nordisk's CagriSema misses vs. Lilly's Zepbound in study
|
-
Novo Nordisk's CagriSema did not match Lilly's Zepbound in a head-to-head study, potentially impacting its commercial prospects in the obesity market.
-
Why it matters:
In obesity, “next-gen” only wins if it clearly beats the benchmark: a head-to-head miss weakens the switch/pricing story for CagriSema and pressures peak-share assumptions versus Lilly’s tirzepatide franchise.
Net: the efficacy bar just moved higher for fast-followers — and Novo likely needs either dose/formulation iteration or a cleaner differentiation wedge (tolerability, durability, adherence) to defend long-term positioning.
-
Source:
BioPharma Dive
-
More:
BioCentury
|
Everything Else that broke
-
MGI to divest Complete Genomics to Swiss Rockets amid Biosecure Act overhang. —
Bloomberg
-
Fortress/Cyprium to sell Rare Pediatric Disease PRV for $205M. —
PR
-
Merck reorganizes human health, splitting oncology from non-oncology operations. —
FT
-
QurAlis posts Phase 1/2 update on QRL-201 (STMN2 rescue strategy) in ALS. —
PR
-
Keytruda exclusivity timeline debated as Merck approaches the 2028 patent cliff. —
FT
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
-
Gilead to acquire Arcellx for $7.8B in myeloma cell therapy deal. —
Reuters
-
Astellas ↔ Vir: global collaboration on VIR-5500 (PSMA-targeting dual-masked TCE); $335M upfront/near-term (incl. $240M cash + $75M equity + $20M milestone) + up to $1.37B milestones + royalties. —
Reuters
-
Organon ↔ Sebela: licenses global rights to MIUDELLA (hormone-free copper IUD); $27.5M upfront + up to $505M sales milestones + tiered double-digit royalties. —
PR
-
Sciwind ↔ Pfizer China: commercialization collaboration for ecnoglutide in Mainland China. —
PR
VC / Private Financings
-
Syndex Bio: $15.5M Seed — led by ARCH Venture Partners; joined by +ND Capital, OMX Ventures, Meltwind. —
PR
IPOs / Follow-Ons
-
Generate Biomedicines targets ~$2.2B valuation in Nasdaq IPO (raise up to ~$425M). —
Reuters
-
Fortress/Cyprium sells Rare Pediatric Disease PRV for $205M (asset monetization). —
PR
Academic Corner
- Transposable elements in the dark genome. — Nature Biotech
- ChatGPT Health performance in a structured test of triage recommendations. — Nature Medicine
|
